DISCRIPTIVE CASE SERIES STUDY: ROLE OF RIFAXIMIN IN HEPATIC ENCEPHALOPATHY

Journal Title: World Journal of Pharmaceutical and Medical Research - Year 2018, Vol 4, Issue 11

Abstract

Background: Hepatic encephalopathy is the second most common major complication in cirrhotic patients and it significantly impacts quality of life. Medicinal approaches for hepatic encephalopathy treatment and prevention mainly depends on ammonia-lowering strategies and non-absorbable disaccharides are currently considered the cornerstone therapy. Non-absorbable antibiotics, such as neomycin and paramycin, are effective in treatment of acute hepatic encephalopathy episodes but their prolonged use has serious side-effects. To overcome these limitations, rifaximin use has been proposed. Objective: To determine the efficacy of rifaximin in cases of chronic liver disease presenting with hepatic encephalopathy. Methodology: In this descriptive cases series study, which was conducted at Department of Medicine, Jinnah Hospital Lahore from May 2017 to October 2017 for 6 months period. The cases of both genders with age range of 25–70 years, having CLD (Child Pugh Class B & C) and acute hepatic encephalopathy of grade II or more irrespective of the cause were included in this study. Hepatic encephalopathy was labeled according to the West Haven Criteria. The cases of hepatic encephalopathy were given Rifaximin in a dose of 550 thrice a day for 7 days and complete resolution of hepatic encephalopathy at 7th day was labeled as positive efficacy. Data was analyzed by using SPSS 20. Results: In this study, there were total 254 cases out of which 144 (56.6%) were males and 110 (43.33%) females. There were 104 cases in Child Pugh class B and 150 cases in Child Pugh class C. Efficacy of rifaximin was seen in 129 (50.7%) cases. The efficacy was significantly high in cases that had Child Pugh Class B. Efficacy was also significantly better in grade II encephalopathy 62/86 cases in contrast to 53/71 cases with grade III. Conclusion: Rifaximin is good antibiotic for gut flora but it relieves hepatic encephalopathy in only half of cases. It is significantly better in cases with Child pugh class B and with encephalopathy grade III.

Authors and Affiliations

Dr. Hira Fatima Zaidi

Keywords

Related Articles

THE EFFECTIVENESS OF IVIG ON TREATING KAWASAKI DISEASE AND, PREVENTING CARDIAC ANEURYSM: A REVIEW ARTICLE

Kawasaki disease is one of the common vasculitides in childhood. Many children worldwide are suffering from Kawasaki disease and many lines of treatment are currently given. In this review, we discussed IVIG, either with...

ANALYZING RUMORS AND GOSSIP AMONG GROUPS OF WHATSAPP, SAUDI ARABIA

Background: The study of rumors has a long history in all the major social sciences, including psychology, social anthropology, geography, sociology, sociolinguistics. Objective: To exposure rumors and gossip among four...

PREPARATION OF ROSUVASTATIN INTERMEDIATES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALT: A REVIEW

The present studies describe class by design-oriented progress and characterization of rosuvastatin calcium.[1] Rosuvastatin has several contraindications which include hypersensitivity to rosuvastatin. In this review, a...

GENETIC POLYMORPHISMS ASSOCIATED WITH CHLOROQUINE RESISTANCE AMONG PLASMODIUM FALCIPARUM ISOLATES FROM ALJUNAYNAH DISTRICT, WEST DARFUR STATE, SUDAN

Chloroquine CQ resistance has been shown to be associated with point mutations in Pfcrt and Pfmdr1. These genes encode for digestive vacuole transmembrane proteins Pfcrt and Pgh1 respectively. Polymorphisms were examined...

CAUSES AND TREATMENT OF PILES (ARSH) A REVIEW

Hemorrhoids (Arsh) are very common Problem in modern life style. It is very common ailment of rectum affected as much as half of the population by the age 50 year. Hemorrhoids are swollen, inflamed veins and capillaries...

Download PDF file
  • EP ID EP665817
  • DOI -
  • Views 195
  • Downloads 0

How To Cite

Dr. Hira Fatima Zaidi (2018). DISCRIPTIVE CASE SERIES STUDY: ROLE OF RIFAXIMIN IN HEPATIC ENCEPHALOPATHY. World Journal of Pharmaceutical and Medical Research, 4(11), 56-59. https://europub.co.uk/articles/-A-665817